Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APT Alpha Pro Tech	$4.61 +1.1%	$4.73	$4.06 ▼ $6.44	$48.28M	0.24	27,092 shs	30,042 shs
INO Inovio Pharmaceuticals	$1.86 +14.8%	$1.67	$1.30 ▼ $8.01	$68.21M	1.38	1.85 million shs	11.66 million shs
MHUA Meihua International Medical Technologies	$0.39	$0.41	$0.25 ▼ $1.26	$12.41M	0.78	164,910 shs	13,843 shs
PYPD PolyPid	$3.45 +0.6%	$3.50	$2.30 ▼ $3.93	$54.86M	1.4	76,898 shs	62,483 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APT Alpha Pro Tech	0.00%	-2.12%	-2.95%	+4.54%	-22.78%
INO Inovio Pharmaceuticals	0.00%	+31.91%	+33.81%	-10.14%	-76.25%
MHUA Meihua International Medical Technologies	0.00%	-6.49%	-13.54%	+2.80%	-40.59%
PYPD PolyPid	0.00%	+7.14%	-4.70%	+22.78%	-8.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APT Alpha Pro Tech	0.9065 of 5 stars	0.0	3.0	0.0	0.6	0.8	1.9
INO Inovio Pharmaceuticals	4.0423 of 5 stars	3.3	4.0	4.4	2.4	0.0	0.6
MHUA Meihua International Medical Technologies	0.7951 of 5 stars	0.0	3.0	0.0	1.9	1.7	0.6
PYPD PolyPid	2.869 of 5 stars	3.6	5.0	0.0	1.8	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APT Alpha Pro Tech	0.00	N/A	N/A	N/A
INO Inovio Pharmaceuticals	2.60	Moderate Buy	$8.80	373.12% Upside
MHUA Meihua International Medical Technologies	0.00	N/A	N/A	N/A
PYPD PolyPid	3.17	Buy	$12.40	259.42% Upside

Current Analyst Ratings Breakdown

Latest MHUA, INO, PYPD, and APT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	PYPD PolyPid	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $13.00
8/14/2025	PYPD PolyPid	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/14/2025	INO Inovio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.00
8/13/2025	PYPD PolyPid	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/9/2025	INO Inovio Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$5.00
6/18/2025	PYPD PolyPid	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$12.00 ➝ $9.00
6/17/2025	PYPD PolyPid	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$16.00 ➝ $14.00
6/9/2025	PYPD PolyPid	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $13.00
6/5/2025	PYPD PolyPid	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
6/2/2025	PYPD PolyPid	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$11.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APT Alpha Pro Tech	$58.56M	0.82	$0.36 per share	12.80	$5.29 per share	0.87
INO Inovio Pharmaceuticals	$220K	310.03	N/A	N/A	$1.90 per share	0.98
MHUA Meihua International Medical Technologies	$96.90M	0.13	$0.46 per share	0.85	$6.34 per share	0.06
PYPD PolyPid	N/A	N/A	N/A	N/A	$0.75 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APT Alpha Pro Tech	$4.19M	$0.34	12.46	∞	N/A	6.99%	6.70%	5.76%	N/A
INO Inovio Pharmaceuticals	-$107.25M	-$2.61	N/A	N/A	N/A	N/A	-163.32%	-96.41%	N/A
MHUA Meihua International Medical Technologies	$10.84M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PYPD PolyPid	-$29.02M	-$3.83	N/A	∞	N/A	N/A	-453.95%	-138.92%	N/A

Latest MHUA, INO, PYPD, and APT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	PYPD PolyPid	-$0.53	-$0.78	-$0.25	-$0.78	N/A	N/A
8/12/2025	Q2 2025	INO Inovio Pharmaceuticals	-$0.63	-$0.61	+$0.02	-$0.61	$0.01 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APT Alpha Pro Tech	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MHUA Meihua International Medical Technologies	N/A	N/A	N/A	N/A	N/A
PYPD PolyPid	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APT Alpha Pro Tech	N/A	19.00	11.21
INO Inovio Pharmaceuticals	N/A	1.66	2.63
MHUA Meihua International Medical Technologies	N/A	5.26	5.21
PYPD PolyPid	N/A	2.28	0.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APT Alpha Pro Tech	22.69%
INO Inovio Pharmaceuticals	26.79%
MHUA Meihua International Medical Technologies	1.17%
PYPD PolyPid	26.47%

Insider Ownership

Company	Insider Ownership
APT Alpha Pro Tech	15.00%
INO Inovio Pharmaceuticals	2.30%
MHUA Meihua International Medical Technologies	66.56%
PYPD PolyPid	24.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APT Alpha Pro Tech	120	10.47 million	9.46 million	Optionable
INO Inovio Pharmaceuticals	320	36.67 million	35.83 million	Optionable
MHUA Meihua International Medical Technologies	620	31.90 million	10.67 million	Not Optionable
PYPD PolyPid	80	15.90 million	11.97 million	No Data

MHUA, INO, PYPD, and APT Headlines

Recent News About These Companies

Research Analysts Issue Forecasts for PolyPid Q3 Earnings

August 17 at 8:58 AM | marketbeat.com

PolyPid (NASDAQ:PYPD) Rating Lowered to "Sell" at Wall Street Zen

August 17 at 2:36 AM | marketbeat.com

Equities Analysts Issue Forecasts for PolyPid Q3 Earnings

August 17 at 2:23 AM | americanbankingnews.com

PolyPid (NASDAQ:PYPD) Given "Buy" Rating at HC Wainwright

August 15 at 2:29 PM | marketbeat.com

PolyPid's (PYPD) "Buy" Rating Reaffirmed at HC Wainwright

August 15 at 2:51 AM | americanbankingnews.com

PolyPid price target raised to $10 from $9 at Roth Capital

August 14, 2025 | msn.com

PolyPid Releases Mid-2025 Financial Update

August 14, 2025 | theglobeandmail.com

PolyPid Reports Strong Phase 3 Results and Financial Update

August 14, 2025 | msn.com

PolyPid Ltd. (NASDAQ:PYPD) Q2 2025 Earnings Call Transcript

August 14, 2025 | msn.com

PolyPid Ltd (PYPD) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses

August 14, 2025 | finance.yahoo.com

PolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript

August 13, 2025 | seekingalpha.com

PolyPid sees cash runway ‘well into’ 2026

August 13, 2025 | msn.com

PolyPid Reports Positive Phase 3 Results and Strengthens Leadership

August 13, 2025 | tipranks.com

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 13, 2025 | globenewswire.com

PolyPid Ltd.: PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

August 12, 2025 | finanznachrichten.de

PolyPid appoints Tweezer-Zaks as Chief Medical Officer

August 12, 2025 | msn.com

PolyPid Appoints New Chief Medical Officer Amid Strategic Advancements

August 12, 2025 | msn.com

PolyPid Ltd. Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

August 12, 2025 | quiverquant.comQ

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

August 12, 2025 | globenewswire.com

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

July 30, 2025 | globenewswire.com

PYPD: Positive Topline Data From D-PLEX₁₀₀ Trial Contributes to Multiple Subsequent Benefits

July 16, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MHUA, INO, PYPD, and APT Company Descriptions

Alpha Pro Tech NYSE:APT

$4.61 +0.05 (+1.10%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$4.58 -0.03 (-0.54%)

As of 08/15/2025 06:01 PM Eastern

Alpha Pro Tech, Ltd., together with its subsidiaries, develops, manufactures, and markets a range of disposable protective apparel, infection control, and building supply products in the United States and internationally. The company operates through Disposable Protective Apparel and Building Supply segments. The Disposable Protective Apparel segment provides shoe covers, bouffant caps, coveralls, frocks, lab coats, and gowns, hoods, as well as face masks and shields. The Building Supply segment offers construction weatherization products, such as housewrap and housewrap accessories, including window and door flashing, and seam tape, synthetic roof underlayment, and self-adhered roof underlayment, as well as other woven material. The company markets its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; building and re-roofing sites. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is headquartered in Markham, Canada.

Inovio Pharmaceuticals NASDAQ:INO

$1.86 +0.24 (+14.81%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.90 +0.03 (+1.88%)

As of 08/15/2025 07:59 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Meihua International Medical Technologies NASDAQ:MHUA

$0.39 0.00 (0.00%)

Closing price 08/15/2025 03:42 PM Eastern

Extended Trading

$0.39 0.00 (0.00%)

As of 08/15/2025 07:05 PM Eastern

Meihua International Medical Technologies Co., Ltd. engages in the manufacture, sells, and marketing of medical consumables in the People's Republic of China. The company offers class I, II, and III disposable medical devices. Its products include non-bottled products, such as brushes and ID bracelets; and polyethylene bottled products, such as eye drop and tablet bottles, as well as electronic pumps. The company also distributes disposable medical devices sourced from other manufacturers to customers in China. In addition, it offers COVID-19 products comprising disposable medical masks. The company serves hospitals, pharmacies, medical institutions, and medical equipment companies. It also exports its products to Europe, North America, South America, Asia, Africa, and Oceania. The company was founded in 1991 and is based in Yangzhou, the People's Republic of China. Meihua International Medical Technologies Co., Ltd. operates as a subsidiary of Bright Accomplish Limited.

PolyPid NASDAQ:PYPD

$3.45 +0.02 (+0.58%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$3.44 -0.02 (-0.43%)

As of 08/15/2025 04:10 PM Eastern

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time